UEMS Medical Specialty
Gastroenterology — Page 2
Precision microbiome interventions, short-chain fatty acid (SCFA) delivery, enteric coating technologies, and gut–brain axis modulation for gastrointestinal and liver health.
32
dossiers
Transmucosal Delivery & Dosage Form Engineering
Piperine-Mediated Potentiation of Direct Oral Anticoagulants: A Clinically Unrecognized Hemorrhagic Risk
Piperine, marketed as a 'bio-enhancer' in nutraceuticals, dangerously potentiates DOACs by inhibiting P-gp and CYP3A4, leading to critical hemorrhagic risk due to uncontrolled increases in drug exposure. This unrecognized interaction demands safer alternatives for enhancing polyphenol bioavailability.
Post-GLP-1 Metabolic Optimization
Triple Agonists and Next-Generation Oral GLP-1s: Advancements in Metabolic Disorder Therapeutics
Formulating complex multi-receptor agonists and high-potency oral GLP-1 peptides requires advanced delivery systems to ensure bioavailability, stability, and patient adherence while mitigating gastrointestinal side effects.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Ketogenic Diet-Specified Interventions in Neurodegenerative Disease Mechanisms
Developing a formulation that achieves consistent and measurable ketosis while optimizing bioavailability and tolerability in neurodegenerative conditions is a key challenge.
Precision Microbiome & Gut-Brain Axis
Nutrition and Psychiatric Disorders: A Comprehensive Narrative Review of the Evidence Through 2026
Optimal dietary interventions for psychiatric disorders remain poorly standardized and show high variability in effectiveness.
Intracellular Defense & IV-Alternatives
Oxidative Stress Mitigation in Nutraceutical Stability: Packaging and Formulation Strategies
Nutraceutical dosage forms face significant degradation due to oxidative stress, driven by moisture, oxygen, and light. This presents a challenge for maintaining stability across supply-chain conditions and long shelf lives.
Precision Microbiome & Gut-Brain Axis
Enteric Delivery of Butyrate: Overcoming Gastrointestinal Barriers for Vagal Activation
Free butyrate salts dissolve prematurely in the upper gastrointestinal tract, limiting their availability for distal gut signaling. Additionally, their pungent odor and taste present significant challenges for patient adherence in chronic applications.
Post-GLP-1 Metabolic Optimization
Semaglutide: Gastrointestinal Effects and Post-Discontinuation Weight Regain, 2026
Developing GLP-1 formulations that balance robust metabolic benefits with reduced gastrointestinal side effects and mitigate post-discontinuation weight regain remains a significant challenge. The interplay between appetite modulation, gastrointestinal motility, and adverse event profiles adds complexity to product optimization.
Precision Microbiome & Gut-Brain Axis
Gut-Brain Axis in ADHD: Microbiota-Mediated Dopaminergic Pathway Modulation
Developing scientifically validated microbiome-targeted interventions for ADHD involves addressing the challenges of heterogeneity in clinical outcomes and identifying precise microbial mechanisms. Formulating stable, effective probiotics or synbiotics with demonstrated clinical benefits remains a major hurdle.
No dossiers match the selected MeSH topic in this page. Try another tag or clear the filter.
Custom Formulation Available
Need a Dossier Built Around Your Molecule?
Our R&D team will conduct a Paid Discovery Audit and build a proprietary clinical dossier for your specific active ingredient or therapeutic target. Full IP transfer included.
RELATED RESOURCES